Indivior Pharmaceuticals (INDV) continues to attract attention after its recent share price move, with the stock last closing at $41.29.

Over the past year, Indivior Pharmaceuticals has shifted from short-term volatility to stronger momentum, with a 90-day share price return of 42.53% and a 1-year total shareholder return of 201.61% pointing to a significantly improved market perception of its prospects and risks.

If this kind of momentum has you looking further across the market, it could be worth scanning the 39 healthcare AI stocks as a next step for new healthcare opportunities.

With Indivior Pharmaceuticals posting a 1-year total shareholder return above 200% and trading at a discount to the average analyst price target, investors may be asking whether there is still a buying opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 17.4% Undervalued

Against the last close at $41.29, the most followed narrative on Indivior Pharmaceuticals points to a fair value of $50.00, framing the recent price move as only part of the story.

The Indivior Action Agenda includes Phase 1, which is focused on simplifying the business, and Phase II, Accelerate, which is set to start in 2026. This plan is expected to reduce nonessential spend by at least US$150 million a year and cap 2026 operating expenses at US$450 million, which directly supports adjusted EBITDA growth and free cash flow.

Want to see what sits behind that cost plan and fair value? The narrative leans heavily on earnings expansion, margin reset and a different profit multiple than today. Curious how those pieces connect to $50.00.

Result: Fair Value of $50.00 (UNDERVALUED)

However, the Indivior Pharmaceuticals story could change quickly if long acting injectable adoption stalls, or if cost cuts begin to limit SUBLOCADE support and pipeline progress.

Next Steps

If the mix of enthusiasm and caution around Indivior Pharmaceuticals has you thinking, do not wait too long to weigh both sides and test your own thesis with the 4 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Indivior Pharmaceuticals?

If Indivior Pharmaceuticals has sharpened your focus, keep that momentum going by lining up a few more candidates so you are not relying on just one story.

• Target companies that combine quality with a potential price gap by checking the 43 high quality undervalued stocks to see which stocks currently sit on investors' blind spot lists.
• Strengthen your income stream by scanning the 9 dividend fortresses and see which companies offer higher yields without ignoring balance sheet discipline.
• Sharpen your watchlist with resilient businesses by running through the 67 resilient stocks with low risk scores before the next wave of attention crowds into these ideas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.